产品说明书
Larotrectinib
 |
同义名 : | LOXO-101;ARRY-470;Vitrakvi |
| CAS号 : | 1223403-58-4 | |
| 货号 : | A205378 | |
| 分子式 : | C21H22F2N6O2 | |
| 纯度 : | 98% | |
| 分子量 : | 428.435 | |
| MDL号 : | - | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 4 mg/mL(9.34 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Larotrectinib (LOXO-101) is an ATP-competitive oral inhibitor targeting the tropomyosin-related kinase (TRK) family of receptor kinases (TRKA, B, and C). It exhibits low nanomolar 50% inhibitory concentrations against all three isoforms and demonstrates 1,000-fold or greater selectivity relative to other kinases[1][2]. Assessment of cell proliferation post-treatment with Larotrectinib (LOXO-101) reveals a dose-dependent suppression across all three cell lines. The IC50 values are below 100 nM for CUTO-3.29 and below 10 nM for KM12 and MO-91, aligning with the established potency of this drug against the TRK kinase family[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.33mL 0.47mL 0.23mL |
11.67mL 2.33mL 1.17mL |
23.34mL 4.67mL 2.33mL |
